Beyond the guidelines: Vascular function as the central determinant and therapeutic target in hypertension

Yukihito Higashi1,2

  • 1Department of Regenerative Medicine, Division of Radiation Medical Science, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. yhigashi@hiroshima-u.ac.jp.

Insights

Hypertension is a systemic vascular disorder, not just high blood pressure. Focusing on vascular health, beyond blood pressure targets, is key to reducing cardiovascular risk and improving treatment.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Hypertension Research

Background:

  • Traditional hypertension management focuses on brachial blood pressure, leaving residual cardiovascular risk.
  • Emerging evidence highlights hypertension as a systemic vascular wall disorder involving endothelial dysfunction, oxidative stress, and inflammation.
  • Vascular dysfunction actively drives hypertension initiation and progression, beyond elevated pressure alone.

Purpose of the Study:

  • To propose a paradigm shift from pressure-centric to vessel-centric hypertension management.
  • To review vascular phenotypes, assessment strategies, and therapeutic approaches targeting vascular restoration.
  • To explore concepts like vascular age, residual risk, precision vascular medicine, and future AI integration.

Main Methods:

  • Review of current scientific literature on hypertension pathophysiology and management.
  • Analysis of emerging evidence on vascular dysfunction mechanisms.
  • Discussion of macrovascular and microvascular assessment techniques.

Main Results:

  • Hypertension involves complex interactions: endothelial nitric oxide deficiency, redox imbalance, inflammation, and mineralocorticoid receptor signaling.
  • Microvascular rarefaction and arterial stiffening contribute to peripheral resistance and target organ injury.
  • These processes create a self-reinforcing cycle sustaining hypertension.

Conclusions:

  • Recognizing vascular dysfunction as central to hypertension refines risk stratification and therapeutic success.
  • A vessel-centric approach, targeting vascular restoration alongside blood pressure reduction, represents the next frontier in cardiovascular medicine.
  • Precision vascular medicine and AI integration hold promise for future hypertension management.

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...